Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway.

Alvarez M, Simonetta F, Baker J, Pierini A, Wenokur AS, Morrison AR, Murphy WJ, Negrin RS.

JCI Insight. 2019 Jun 18;5. pii: 127729. doi: 10.1172/jci.insight.127729.

2.

Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.

Meyer EH, Laport G, Xie BJ, MacDonald K, Heydari K, Sahaf B, Tang SW, Baker J, Armstrong R, Tate K, Tadisco C, Arai S, Johnston L, Lowsky R, Muffly L, Rezvani AR, Shizuru J, Weng WK, Sheehan K, Miklos D, Negrin RS.

JCI Insight. 2019 May 16;4(10). pii: 127244. doi: 10.1172/jci.insight.127244. eCollection 2019 May 16.

3.

Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms.

Narayan R, Benjamin JE, Shah O, Tian L, Tate K, Armstrong R, Xie BJ, Lowsky R, Laport G, Negrin RS, Meyer EH.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1293-1303. doi: 10.1016/j.bbmt.2019.03.027. Epub 2019 Apr 3.

PMID:
30951840
4.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
5.

Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation.

Muffly L, Sheehan K, Armstrong R, Jensen K, Tate K, Rezvani AR, Miklos D, Arai S, Shizuru J, Johnston L, Meyer E, Weng WK, Laport GG, Negrin RS, Strober S, Lowsky R.

Blood Adv. 2018 Mar 27;2(6):681-690. doi: 10.1182/bloodadvances.2017012104.

6.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

7.

HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.

Spinner MA, Fernández-Viña M, Creary LE, Quinn O, Elder L, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Shizuru JA, Weng WK, Laport GG, Strober S, Lowsky R, Rezvani AR.

Blood Adv. 2017 Jul 25;1(17):1347-1357. doi: 10.1182/bloodadvances.2017007716. eCollection 2017 Jul 25.

8.

T cells expressing chimeric antigen receptor promote immune tolerance.

Pierini A, Iliopoulou BP, Peiris H, Pérez-Cruz M, Baker J, Hsu K, Gu X, Zheng PP, Erkers T, Tang SW, Strober W, Alvarez M, Ring A, Velardi A, Negrin RS, Kim SK, Meyer EH.

JCI Insight. 2017 Oct 19;2(20). pii: 92865. doi: 10.1172/jci.insight.92865.

9.

Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation.

Mavers M, Maas-Bauer K, Negrin RS.

Front Immunol. 2017 Jul 31;8:900. doi: 10.3389/fimmu.2017.00900. eCollection 2017. Review.

10.

Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation.

Simonetta F, Alvarez M, Negrin RS.

Front Immunol. 2017 Apr 25;8:465. doi: 10.3389/fimmu.2017.00465. eCollection 2017. Review.

11.

Foxp3+ regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis.

Pierini A, Nishikii H, Baker J, Kimura T, Kwon HS, Pan Y, Chen Y, Alvarez M, Strober W, Velardi A, Shizuru JA, Wu JY, Chiba S, Negrin RS.

Nat Commun. 2017 May 9;8:15068. doi: 10.1038/ncomms15068.

12.

Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells.

Du J, Paz K, Thangavelu G, Schneidawind D, Baker J, Flynn R, Duramad O, Feser C, Panoskaltsis-Mortari A, Negrin RS, Blazar BR.

Blood. 2017 Jun 8;129(23):3121-3125. doi: 10.1182/blood-2016-11-752444. Epub 2017 Apr 17.

13.

Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.

Chen YB, Efebera YA, Johnston L, Ball ED, Avigan D, Lekakis LJ, Bachier CR, Martin P, Duramad O, Ishii Y, Han S, Jung YJ, Lee D, Kunkel L, Negrin RS, Bui JD.

Biol Blood Marrow Transplant. 2017 Apr;23(4):625-634. doi: 10.1016/j.bbmt.2017.01.069. Epub 2017 Jan 16.

14.

Welcome to Blood Advances.

Negrin RS.

Blood Adv. 2016 Nov 22;1(1):1. doi: 10.1182/bloodadvances.2016001677. eCollection 2016 Nov 29. No abstract available.

15.

Introduction to a review series on chronic GVHD: from pathogenic B-cell receptor signaling to novel therapeutic targets.

Zeiser R, Negrin RS.

Blood. 2017 Jan 5;129(1):1-2. doi: 10.1182/blood-2016-10-735696. Epub 2016 Nov 7. No abstract available.

16.

Blood Stem Cell Activity Is Arrested by Th1-Mediated Injury Preventing Engraftment following Nonmyeloablative Conditioning.

Müller AM, Florek M, Kohrt HE, Küpper NJ, Filatenkov A, Linderman JA, Hadeiba H, Negrin RS, Shizuru JA.

J Immunol. 2016 Nov 15;197(10):4151-4162. Epub 2016 Oct 10.

17.

DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease.

Nishikii H, Kim BS, Yokoyama Y, Chen Y, Baker J, Pierini A, Alvarez M, Mavers M, Maas-Bauer K, Pan Y, Chiba S, Negrin RS.

Blood. 2016 Dec 15;128(24):2846-2858. Epub 2016 Oct 19.

18.

TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment.

Pierini A, Strober W, Moffett C, Baker J, Nishikii H, Alvarez M, Pan Y, Schneidawind D, Meyer E, Negrin RS.

Blood. 2016 Aug 11;128(6):866-71. doi: 10.1182/blood-2016-04-711275. Epub 2016 Jun 30.

19.

NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment.

Pierini A, Alvarez M, Negrin RS.

Stem Cells Int. 2016;2016:9025835. doi: 10.1155/2016/9025835. Epub 2016 Jan 5. Review.

20.

Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization.

Kuipers HF, Rieck M, Gurevich I, Nagy N, Butte MJ, Negrin RS, Wight TN, Steinman L, Bollyky PL.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1339-44. doi: 10.1073/pnas.1525086113. Epub 2016 Jan 19.

21.

Regulatory T Cell Immunotherapy in Immune-Mediated Diseases.

Pierini A, Schneidawind D, Nishikii H, Negrin RS.

Curr Stem Cell Rep. 2015 Dec 1;1(4):177-186. Epub 2015 Sep 12.

22.

Graft-versus-host disease versus graft-versus-leukemia.

Negrin RS.

Hematology Am Soc Hematol Educ Program. 2015;2015:225-30. doi: 10.1182/asheducation-2015.1.225. Review.

PMID:
26637726
23.

Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.

Kurnellas MP, Ghosn EE, Schartner JM, Baker J, Rothbard JJ, Negrin RS, Herzenberg LA, Fathman CG, Steinman L, Rothbard JB.

Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):15016-23. doi: 10.1073/pnas.1521206112. Epub 2015 Nov 30.

24.

MLL leukemia induction by genome editing of human CD34+ hematopoietic cells.

Buechele C, Breese EH, Schneidawind D, Lin CH, Jeong J, Duque-Afonso J, Wong SH, Smith KS, Negrin RS, Porteus M, Cleary ML.

Blood. 2015 Oct 1;126(14):1683-94. doi: 10.1182/blood-2015-05-646398. Epub 2015 Aug 26.

25.

Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.

Rezvani AR, Kanate AS, Efron B, Chhabra S, Kohrt HE, Shizuru JA, Laport GG, Miklos DB, Benjamin JE, Johnston LJ, Arai S, Weng WK, Negrin RS, Strober S, Lowsky R.

Bone Marrow Transplant. 2015 Oct;50(10):1286-92. doi: 10.1038/bmt.2015.149. Epub 2015 Jul 6.

26.

Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.

Kim BS, Nishikii H, Baker J, Pierini A, Schneidawind D, Pan Y, Beilhack A, Park CG, Negrin RS.

Blood. 2015 Jul 23;126(4):546-57. doi: 10.1182/blood-2015-04-637587. Epub 2015 Jun 10.

27.

Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.

Pierini A, Colonna L, Alvarez M, Schneidawind D, Nishikii H, Baker J, Pan Y, Florek M, Kim BS, Negrin RS.

J Immunol. 2015 Jul 1;195(1):347-55. doi: 10.4049/jimmunol.1402861. Epub 2015 May 20.

28.

Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.

Percival MM, Medeiros BC, Tian L, Robeson S, Laport GG, Johnston LJ, Shizuru JA, Miklos DB, Arai S, Weng WK, Negrin RS, Lowsky R.

Bone Marrow Transplant. 2015 Jul;50(7):1004-1006. doi: 10.1038/bmt.2015.62. Epub 2015 Apr 20. No abstract available.

29.

Engraftment of embryonic stem cells and differentiated progeny by host conditioning with total lymphoid irradiation and regulatory T cells.

Pan Y, Leveson-Gower DB, de Almeida PE, Pierini A, Baker J, Florek M, Nishikii H, Kim BS, Ke R, Wu JC, Negrin RS.

Cell Rep. 2015 Mar 24;10(11):1793-802.

30.

Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality.

Schneidawind D, Baker J, Pierini A, Buechele C, Luong RH, Meyer EH, Negrin RS.

Blood. 2015 May 28;125(22):3491-500. doi: 10.1182/blood-2014-11-612762. Epub 2015 Mar 20.

31.

ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation.

Logan AC, Wang Z, Alimoghaddam K, Wong RM, Lai T, Negrin RS, Grumet C, Logan BR, Zhang MJ, Spellman SR, Lee SJ, Miklos DB; Center for International Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2015 Apr;21(4):746-54. doi: 10.1016/j.bbmt.2014.12.036. Epub 2015 Jan 5.

32.

CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.

Schneidawind D, Pierini A, Alvarez M, Pan Y, Baker J, Buechele C, Luong RH, Meyer EH, Negrin RS.

Blood. 2014 Nov 20;124(22):3320-8. doi: 10.1182/blood-2014-05-576017. Epub 2014 Oct 7.

33.

Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models.

Florek M, Sega EI, Leveson-Gower DB, Baker J, Müller AM, Schneidawind D, Meyer E, Negrin RS.

Blood. 2014 Sep 11;124(11):1832-42. doi: 10.1182/blood-2014-02-555128. Epub 2014 Jul 16.

34.

Treatment of 4T1 metastatic breast cancer with combined hypofractionated irradiation and autologous T-cell infusion.

Filatenkov A, Baker J, Müller AM, Ahn GO, Kohrt H, Dutt S, Jensen K, Dejbakhsh-Jones S, Negrin RS, Shizuru JA, Engleman EG, Strober S.

Radiat Res. 2014 Aug;182(2):163-9. doi: 10.1667/RR13471.1. Epub 2014 Jul 3.

35.

Introduction to the review series on "Advances in hematopoietic cell transplantation".

Negrin RS.

Blood. 2014 Jul 17;124(3):307. doi: 10.1182/blood-2014-05-566679. Epub 2014 Jun 9. No abstract available.

36.

European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

Medeiros BC, Tian L, Robenson S, Laport GG, Johnston LJ, Shizuru JA, Miklos DB, Arai S, Benjamin JE, Weng WK, Negrin RS, Lowsky R.

Blood Cancer J. 2014 May 30;4:e216. doi: 10.1038/bcj.2014.35. No abstract available.

37.

Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance.

de Almeida PE, Meyer EH, Kooreman NG, Diecke S, Dey D, Sanchez-Freire V, Hu S, Ebert A, Odegaard J, Mordwinkin NM, Brouwer TP, Lo D, Montoro DT, Longaker MT, Negrin RS, Wu JC.

Nat Commun. 2014 May 30;5:3903. doi: 10.1038/ncomms4903.

38.

A killer choice for cancer immunotherapy.

Schmidt TL, Negrin RS, Contag CH.

Immunol Res. 2014 May;58(2-3):300-6. doi: 10.1007/s12026-014-8507-2. Review.

PMID:
24791943
39.

Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.

Benjamin J, Chhabra S, Kohrt HE, Lavori P, Laport GG, Arai S, Johnston L, Miklos DB, Shizuru JA, Weng WK, Negrin RS, Lowsky R.

Biol Blood Marrow Transplant. 2014 Jun;20(6):837-43. doi: 10.1016/j.bbmt.2014.02.023. Epub 2014 Mar 7.

40.

Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment.

Müller AM, Poyser J, Küpper NJ, Burnett C, Ko RM, Kohrt HE, Florek M, Zhang P, Negrin RS, Shizuru JA.

Blood. 2014 May 1;123(18):2882-92. doi: 10.1182/blood-2013-10-530212. Epub 2014 Mar 3.

41.

Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation.

Sega EI, Leveson-Gower DB, Florek M, Schneidawind D, Luong RH, Negrin RS.

PLoS One. 2014 Jan 27;9(1):e86551. doi: 10.1371/journal.pone.0086551. eCollection 2014.

42.

Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation.

Schneidawind D, Pierini A, Negrin RS.

Blood. 2013 Oct 31;122(18):3116-21. doi: 10.1182/blood-2013-08-453126. Epub 2013 Sep 25. Review.

43.

Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells.

Leveson-Gower DB, Sega EI, Kalesnikoff J, Florek M, Pan Y, Pierini A, Galli SJ, Negrin RS.

Blood. 2013 Nov 21;122(22):3659-65. doi: 10.1182/blood-2013-08-519157. Epub 2013 Sep 12.

44.

IL-17 gene ablation does not impact Treg-mediated suppression of graft-versus-host disease after bone marrow transplantation.

Colonna L, Florek M, Leveson-Gower DB, Sega EI, Baker J, Smith AT, Negrin RS.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1557-65. doi: 10.1016/j.bbmt.2013.07.024. Epub 2013 Aug 3.

45.

A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model.

Bäuerlein CA, Riedel SS, Baker J, Brede C, Garrote AL, Chopra M, Ritz M, Beilhack GF, Schulz S, Zeiser R, Schlegel PG, Einsele H, Negrin RS, Beilhack A.

BMC Med. 2013 May 21;11:134. doi: 10.1186/1741-7015-11-134.

46.

A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease.

Meyer EH, Hsu AR, Liliental J, Löhr A, Florek M, Zehnder JL, Strober S, Lavori P, Miklos DB, Johnson DS, Negrin RS.

Blood. 2013 Jun 13;121(24):4955-62. doi: 10.1182/blood-2013-03-489757. Epub 2013 May 7.

47.

A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells.

Lask A, Ophir E, Or-Geva N, Cohen-Fredarow A, Afik R, Eidelstein Y, Reich-Zeliger S, Nathansohn B, Edinger M, Negrin RS, Hagin D, Reisner Y.

Blood. 2013 Apr 11;121(15):3033-40. doi: 10.1182/blood-2012-06-432443. Epub 2013 Feb 27.

48.

Mapping immune processes in intact tissues at cellular resolution.

Brede C, Friedrich M, Jordán-Garrote AL, Riedel SS, Bäuerlein CA, Heinze KG, Bopp T, Schulz S, Mottok A, Kiesel C, Mattenheimer K, Ritz M, von Krosigk V, Rosenwald A, Einsele H, Negrin RS, Harms GS, Beilhack A.

J Clin Invest. 2012 Dec;122(12):4439-46. doi: 10.1172/JCI65100. Epub 2012 Nov 12.

49.

Cancer vaccines and T cell therapy.

Rezvani K, Brody JD, Kohrt HE, Logan AC, Advani R, Czerwinski DK, Weng WK, Negrin RS, Carlton V, Faham M, Levy R, Barrett J.

Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S97-S101. doi: 10.1016/j.bbmt.2012.09.020. Epub 2012 Oct 3. Review. No abstract available.

50.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.

Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB.

Blood. 2012 Jun 21;119(25):6145-54. doi: 10.1182/blood-2011-12-395970. Epub 2012 May 4.

Supplemental Content

Loading ...
Support Center